Mass Tort brief
Bard Catheter Verdict and Hair Relaxer Suits Expand Mass Tort Liability
A $40M bellwether verdict against C.R. Bard and a novel state lawsuit from Arizona highlight escalating legal liabilities across medical device, cosmetic, and consumer sectors.
Mass Tort
Arizona's government lawsuit opens a state enforcement front against L'Oréal — threatening statutory penalties alongside 12,000 private cancer claims in federal court.
BackgroundThousands of women have filed personal injury suits alleging chemical straighteners caused uterine and ovarian cancers. State enforcement actions seek statutory consumer protection penalties and mandatory warnings alongside private civil litigation.
- Arizona AG Kristin Mayes filed suit alleging L'Oréal concealed cancer risks while aggressively marketing products like Dark & Lovely primarily to Black women.
- The state enforcement action seeks civil monetary penalties and mandatory health warning labels on chemical relaxer products sold across Arizona.
- L'Oréal already faces more than 12,000 consolidated personal injury claims in Chicago multidistrict litigation, compounding its total legal and financial exposure.
Mass Tort
The $40M bellwether verdict against C.R. Bard establishes high per-claim liability — forcing Becton Dickinson toward a costly settlement across 4,000 catheter injury suits.
BackgroundMultidistrict litigation consolidates thousands of personal injury claims into representative bellwether trials to test legal theories and damages. These early verdicts heavily shape global settlement values between injury plaintiffs and medical device manufacturers.
- The Arizona federal jury found C.R. Bard liable after an implanted catheter fractured internally, causing severe vascular damage that required emergency surgical intervention.
- Parent company Becton Dickinson faces nearly 4,000 pending claims in federal multidistrict litigation alleging port catheter fractures, infections, and systemic tissue injury.
- Federal court dockets have scheduled additional PowerPort bellwether trials through late 2026, keeping continuous settlement pressure on the device manufacturer.
Mass Tort
Johnson & Johnson's Neutrogena settlement resolves Illinois biometric privacy liability — demonstrating how strict state consent laws penalize consumer brands using facial scanning tech.
BackgroundIllinois' Biometric Information Privacy Act prescribes strict statutory damages of up to $5,000 per violation for unauthorized collection of facial scans. Consumer brands using digital scanning features face mounting class action liability across the state.
- The proposed settlement resolves allegations that Neutrogena and NeoStrata Skin360 mobile applications collected and stored facial biometric data without explicit consumer permission.
- Eligible Illinois users who performed facial scans between 2019 and 2023 can submit administrative claims to receive direct cash payments from the settlement fund.
- Kenvue, the consumer health company spun off from Johnson & Johnson, will fund and administer the consumer privacy settlement payments.
Unlock the full brief
Sign in to read every signal, takeaway, and source. Free account — Apple, Google, or email.
